Tags

Type your tag names separated by a space and hit enter

Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
J Clin Psychiatry. 2001; 62 Suppl 2:6-11.JC

Abstract

BACKGROUND

Previously, a double-blind, 6-week, parallel-group trial compared the therapeutic profiles of olanzapine (5-20 mg/day; N = 1,336) and haloperidol (5-20 mg/day; N = 660) in 1996 patients with DSM-III-R schizophrenia (83.1%) or schizophreniform (1.9%) or schizoaffective disorders (15.0%) and showed olanzapine to have a superior, broader spectrum of efficacy as well as a more favorable adverse event profile. The present post hoc analysis examined the efficacy of olanzapine compared with haloperidol in the schizophrenic cohort of that study and in subgroups of schizophrenic patients defined by baseline symptom profile and course of illness.

METHOD

A total of 1,658 patients were included. Patients were included in analyses of change if they had both a baseline and at least 1 postbaseline measurement (N = 1,622; 1,096 olanzapine-treated patients, 526 haloperidol-treated patients). An analysis of variance was used to compare treatment effects on efficacy measurements including the Brief Psychiatric Rating Scale (BPRS; scored 0-6) and the Positive and Negative Syndrome Scale (total, positive subscale, and negative subscale scores).

RESULTS

Olanzapine-treated patients exhibited statistically significantly greater improvements from baseline (last observation carried forward) on all efficacy measurements. Olanzapine-treated patients with predominantly positive, predominantly negative, or mixed symptoms had statistically significantly greater improvements in BPRS total scores compared with similar haloperidol-treated patients. Patients with primarily chronic negative symptoms and patients with chronic or subchronic courses of illness had statistically significantly greater mean improvements from baseline on the BPRS total with olanzapine compared with haloperidol. Furthermore, within the olanzapine treatment group, patients with a subchronic course of illness had greater mean improvements than patients with a chronic course of illness.

CONCLUSION

Olanzapine was more effective than haloperidol in treating a varied spectrum of patients with schizophrenia, including patients with positive, negative, or mixed symptom profiles and either a chronic or subchronic course of illness.

Authors+Show Affiliations

Eli Lilly Spain, Alcobendas, Madrid.No affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase III
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11232753

Citation

Gomez, J C., and A M. Crawford. "Superior Efficacy of Olanzapine Over Haloperidol: Analysis of Patients With Schizophrenia From a Multicenter International Trial." The Journal of Clinical Psychiatry, vol. 62 Suppl 2, 2001, pp. 6-11.
Gomez JC, Crawford AM. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. J Clin Psychiatry. 2001;62 Suppl 2:6-11.
Gomez, J. C., & Crawford, A. M. (2001). Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. The Journal of Clinical Psychiatry, 62 Suppl 2, 6-11.
Gomez JC, Crawford AM. Superior Efficacy of Olanzapine Over Haloperidol: Analysis of Patients With Schizophrenia From a Multicenter International Trial. J Clin Psychiatry. 2001;62 Suppl 2:6-11. PubMed PMID: 11232753.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. AU - Gomez,J C, AU - Crawford,A M, PY - 2001/3/10/pubmed PY - 2001/3/17/medline PY - 2001/3/10/entrez SP - 6 EP - 11 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 62 Suppl 2 N2 - BACKGROUND: Previously, a double-blind, 6-week, parallel-group trial compared the therapeutic profiles of olanzapine (5-20 mg/day; N = 1,336) and haloperidol (5-20 mg/day; N = 660) in 1996 patients with DSM-III-R schizophrenia (83.1%) or schizophreniform (1.9%) or schizoaffective disorders (15.0%) and showed olanzapine to have a superior, broader spectrum of efficacy as well as a more favorable adverse event profile. The present post hoc analysis examined the efficacy of olanzapine compared with haloperidol in the schizophrenic cohort of that study and in subgroups of schizophrenic patients defined by baseline symptom profile and course of illness. METHOD: A total of 1,658 patients were included. Patients were included in analyses of change if they had both a baseline and at least 1 postbaseline measurement (N = 1,622; 1,096 olanzapine-treated patients, 526 haloperidol-treated patients). An analysis of variance was used to compare treatment effects on efficacy measurements including the Brief Psychiatric Rating Scale (BPRS; scored 0-6) and the Positive and Negative Syndrome Scale (total, positive subscale, and negative subscale scores). RESULTS: Olanzapine-treated patients exhibited statistically significantly greater improvements from baseline (last observation carried forward) on all efficacy measurements. Olanzapine-treated patients with predominantly positive, predominantly negative, or mixed symptoms had statistically significantly greater improvements in BPRS total scores compared with similar haloperidol-treated patients. Patients with primarily chronic negative symptoms and patients with chronic or subchronic courses of illness had statistically significantly greater mean improvements from baseline on the BPRS total with olanzapine compared with haloperidol. Furthermore, within the olanzapine treatment group, patients with a subchronic course of illness had greater mean improvements than patients with a chronic course of illness. CONCLUSION: Olanzapine was more effective than haloperidol in treating a varied spectrum of patients with schizophrenia, including patients with positive, negative, or mixed symptom profiles and either a chronic or subchronic course of illness. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/11232753/Superior_efficacy_of_olanzapine_over_haloperidol:_analysis_of_patients_with_schizophrenia_from_a_multicenter_international_trial_ L2 - http://www.psychiatrist.com/jcp/article/pages/2001/v62s02/v62s0202.aspx DB - PRIME DP - Unbound Medicine ER -